Autolus Therapeutics (AUTL) Stock Price, Quote, News & History

Comments

Autolus Therapeutics PLC (AUTL) Stock Price, Quote, News & History

AUTLNASDAQ

Trade with Public

$1.56

0.053.31%

At close: Feb 18, 4:00 PM EST

$1.57

0.00910.58%

After Hours: 7:48 PM EST

OverviewNews Earnings Options Analyst Ratings Short Interest Stock Report

Key Statistics

Open

$1.55

Close

$1.56

Volume / Avg.

1.24M / 2.67M

Day Range

$1.51 - $1.59

52 Wk Range

1.11 - 2.70

Market Cap

$417.61M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

7.64%

Days to Cover

9.02

Recent Autolus Therapeutics PLC News

Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Avi Kapoor

DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-254.18M

Investing Cash Flow (TTM)

-311.67M

Financing Cash Flow (TTM)

27.47M

Free Cash Flow (TTM)

-306.05M

Capital Expenditure (TTM)

-51.87M

Net Change in Cash (TTM)

-538.39M

Analyst Trends and Forecast

1

Oct 25

1

Nov 25

2

Dec 25

1

Jan

1

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$100.30M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.86

PB Ratio (TTM)

1.51

Earnings Yield % (TTM)

-54.97%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.00

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$86.12M

Debt to Equity

0.25

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.55

Close

$1.56

Volume / Avg.

1.24M / 2.67M

Day Range

$1.51 - $1.59

52 Wk Range

1.11 - 2.70

Market Cap

$417.61M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

7.64%

Days to Cover

9.02

About

Sector

Health Care

Industry

Biotechnology

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUT...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Autolus Therapeutics (AUTL) stock?

A

You can purchase shares of Autolus Therapeutics (NASDAQ:AUTL) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Autolus Therapeutics (AUTL) competitors?

A

Other companies in Autolus Therapeutics’s space includes: Zura Bio Ltd (NASDAQ:ZURA), Tectonic Therapeutic Inc (NASDAQ:TECX), Monopar Therapeutics Inc (NASDAQ:MNPR), Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX) and PureTech Health PLC (NASDAQ:PRTC).

Q

What is the forecast, or price target, for Autolus Therapeutics (AUTL) stock?

A

Autolus Therapeutics has a consensus price target of $9.24.

Q

What is the current price for Autolus Therapeutics (AUTL)?

A

The stock price for Autolus Therapeutics (NASDAQ: AUTL) is $1.5691 last updated February 18, 2026 at 7:48 PM EST.

Q

Does Autolus Therapeutics (AUTL) pay a dividend?

A

There are no upcoming dividends for Autolus Therapeutics.

Q

When is Autolus Therapeutics (NASDAQ:AUTL) reporting earnings?

A

Autolus Therapeutics does not have any upcoming earnings scheduled.

Q

Is Autolus Therapeutics (AUTL) going to split?

A

There is no upcoming split for Autolus Therapeutics.

Q

What sector and industry does Autolus Therapeutics (AUTL) operate in?

A

Autolus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Tectonic Therapeutic Inc

NASDAQ:TECX

$21.46

1.61%

Monopar Therapeutics Inc

NASDAQ:MNPR

$55.48

%

Eupraxia Pharmaceuticals Inc

Bicycle Therapeutics PLC

NASDAQ:BCYC

$5.38

%

Lineage Cell Therapeutics Inc

AMEX:LCTX

$1.72

2.38%

Assembly Biosciences Inc

NASDAQ:ASMB

$28.89

%

Key Statistics

Open

$1.55

Close

$1.56

Volume / Avg.

1.24M / 2.67M

Day Range

$1.51 - $1.59

52 Wk Range

1.11 - 2.70

Market Cap

$417.61M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

7.64%

Days to Cover

9.02

Recent Autolus Therapeutics PLC News

Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Avi Kapoor

DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-254.18M

Investing Cash Flow (TTM)

-311.67M

Financing Cash Flow (TTM)

27.47M

Free Cash Flow (TTM)

-306.05M

Capital Expenditure (TTM)

-51.87M

Net Change in Cash (TTM)

-538.39M

Analyst Trends and Forecast

1

Oct 25

1

Nov 25

2

Dec 25

1

Jan

1

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$100.30M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.86

PB Ratio (TTM)

1.51

Earnings Yield % (TTM)

-54.97%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.00

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$86.12M

Debt to Equity

0.25

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.55

Close

$1.56

Volume / Avg.

1.24M / 2.67M

Day Range

$1.51 - $1.59

52 Wk Range

1.11 - 2.70

Market Cap

$417.61M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

7.64%

Days to Cover

9.02

About

Sector

Health Care

Industry

Biotechnology

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUT...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry